BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 235 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $951,283 | -10.0% | 134,362 | +6.0% | 0.00% | 0.0% |
| Q1 2023 | $1,056,670 | +181.0% | 126,699 | +256.2% | 0.00% | +100.0% |
| Q2 2022 | $376,000 | -97.9% | 35,574 | -96.7% | 0.00% | -97.0% |
| Q1 2022 | $17,656,000 | +849.2% | 1,085,846 | +493.7% | 0.03% | +266.7% |
| Q1 2021 | $1,860,000 | +678.2% | 182,905 | +263.8% | 0.01% | +350.0% |
| Q2 2020 | $239,000 | +67.1% | 50,277 | -29.8% | 0.00% | +100.0% |
| Q1 2020 | $143,000 | -94.9% | 71,660 | -67.2% | 0.00% | -97.6% |
| Q2 2014 | $2,785,000 | – | 218,413 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |